Psychopharm review : timely reports in psychopharmacology and device-based therapies最新文献_第4页

D‐Cycloserine Augmentation of Cognitive‐Behavioral Therapy for the Treatment of Anxiety Disorders D -环丝氨酸增强认知行为疗法治疗焦虑症

Psychopharm review : timely reports in psychopharmacology and device-based therapies Pub Date : 2011-08-01 DOI: 10.1097/01.PSYPHR.0000399653.06660.fa

P. Janicak, Natalie C. Dattilo, Rachel C. Manos, E. Storch, A. Goddard

引用次数: 1

The Role of Melatonin in Psychiatric Disorders 褪黑素在精神疾病中的作用

Psychopharm review : timely reports in psychopharmacology and device-based therapies Pub Date : 2011-07-01 DOI: 10.1097/01.PSYPHR.0000399579.42651.8b

P. Janicak, A. Kledzik, M. C. Thorne

引用次数: 6

Lurasidone: The Most Recent Addition to Our Antipsychotic Armamentarium: A Review of the Data 鲁拉西酮:我们抗精神病药库的最新成员:数据回顾

Psychopharm review : timely reports in psychopharmacology and device-based therapies Pub Date : 2011-06-01 DOI: 10.1097/01.PSYPHR.0000397993.50008.5c

S. Fayad, R. Tandon

引用次数: 4

Treatment of Negative Symptoms in Schizophrenia 精神分裂症阴性症状的治疗

Psychopharm review : timely reports in psychopharmacology and device-based therapies Pub Date : 2011-05-01 DOI: 10.1097/01.IDT.0000396484.87192.42

Jeffrey Rado

引用次数: 3

Bipolar Disorder: An Update on Recent Therapeutic Trials 双相情感障碍:最近治疗试验的更新

Psychopharm review : timely reports in psychopharmacology and device-based therapies Pub Date : 2011-04-01 DOI: 10.1097/01.IDT.0000395192.77327.9e

P. Keck, S. McElroy, J. M. Hawkins

引用次数: 0

Tricyclic Antidepressants: An Underutilized Treatment? Part I 三环抗抑郁药:一种未充分利用的治疗方法?第一部分

Psychopharm review : timely reports in psychopharmacology and device-based therapies Pub Date : 2011-02-01 DOI: 10.1097/01.IDT.0000392937.51742.dc

Aaron Plattner, B. Dantz

{"title":"Tricyclic Antidepressants: An Underutilized Treatment? Part I","authors":"Aaron Plattner, B. Dantz","doi":"10.1097/01.IDT.0000392937.51742.dc","DOIUrl":"https://doi.org/10.1097/01.IDT.0000392937.51742.dc","url":null,"abstract":"HISTORY AND BACKGROUND The development of antidepressant medications began in the 1950s with the serendipitous discovery of monoamine oxidase inhibitors (MAOIs) and the tertiary amine class of tricyclic antidepressants (TCAs). Imipramine, the first marketed TCA, was introduced in 1957 as the result of an effort to improve on the phenothiazines. It was subsequently demonstrated to have antidepressant but not antipsychotic effects. The classification of TCAs is based on the molecular structure of 2 benzene rings joined by a 7-member ring containing nitrogen, oxygen, or only carbons. TCAs slow the rate of neuronal reuptake of serotonin and norepinephrine, increasing synaptic levels of both monoamines. TCAs also block histaminic, muscarinic, and 1 -adrenergic receptor sites, accounting for the unwanted adverse effects of weight gain, drowsiness, dry mouth, constipation, and orthostasis (Table 1). Their blockade of sodium channels in myocardial tissue makes these agents proarrhythmic and potentially lethal in overdose. The secondary amines are derived by demethylating the tertiary amines. The secondary amines primarily block norepinephrine reuptake. Compared with the tertiary amines, they have a lower affinity for histaminic, cholinergic, and 1 -adrenergic receptors, and are generally better tolerated. Their affinity for myocardial sodium channels, however, still renders these drugs dangerous in overdose. The toxic-to-therapeutic ratio is well established with the secondary amines. Serum blood levels can be monitored to optimize efficacy while minimizing adverse effects. After participating in this activity, the psychiatrist should be better able to: • Evaluate the role for tricyclic antidepressants in the treatment of major depression. • Assess the adverse effects and risks when using tricyclic antidepressants. • Use tricyclic antidepressants in treatment strategies for patients with depression.","PeriodicalId":90307,"journal":{"name":"Psychopharm review : timely reports in psychopharmacology and device-based therapies","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2011-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/01.IDT.0000392937.51742.dc","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"61612209","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Overview of Psychodermatology 精神皮肤病学综述

Psychopharm review : timely reports in psychopharmacology and device-based therapies Pub Date : 2011-01-01 DOI: 10.1097/01.IDT.0000392647.34560.2c

A. Kleinman

引用次数: 0

The Psychopharmacology Algorithm Project at The Harvard South Shore Program: An Update on Generalized Social Anxiety Disorder 哈佛大学南岸项目的精神药理学算法项目:广泛性社交焦虑障碍的最新进展

Psychopharm review : timely reports in psychopharmacology and device-based therapies Pub Date : 2010-12-01 DOI: 10.1097/01.IDT.0000391328.04097.1e

D. Osser, L. Dunlop

引用次数: 7

Violence Risk Assessment: Part I 暴力风险评估:第一部分

Psychopharm review : timely reports in psychopharmacology and device-based therapies Pub Date : 2010-10-01 DOI: 10.1097/01.IDT.0000388862.58629.3d

J. Howard, J. L. Cavanaugh

{"title":"Violence Risk Assessment: Part I","authors":"J. Howard, J. L. Cavanaugh","doi":"10.1097/01.IDT.0000388862.58629.3d","DOIUrl":"https://doi.org/10.1097/01.IDT.0000388862.58629.3d","url":null,"abstract":"When performing a violence risk assessment, there are competing viewpoints as to which variables should be considered. Such variables are generally integrated into a theoretical model of the patient’s personality and behavior to either stratify the likelihood of becoming violent or inform treatment decisions. In the past, psychiatrists relied solely on unstructured “clinical” judgment, which was harshly described by Ennis and Litwack as having “absolutely no expertise in predicting dangerous behavior” and further marginalized by Lidz and colleagues in a case-controlled study. The introduction of actuarial methods (statistically oriented structured risk assessment), which identify and weigh various factors to minimize error-prone clinician subjectivity, offers promise but remains underutilized by psychiatrists. This may be defensive posturing in response to state ments such as “Actuarial methods are too good and clinical judgment is too poor to risk contaminating the former with the latter.” 3 In 1999, one-third of US psychiatric residents stated that they had no training in violence risk assessment, whereas another third described their training as “inadequate.” This was 4 years after the development of the Historical, Clinical, Risk Management 20-item (HCR-20) violence risk assessment scale, 6 years after the publication of the Violence Risk Appraisal Guide (VRAG), and nearly 20 years after publication of the forerunner of the Psychopathy Checklist. Currently, there is no American Psychiatric Association practice guideline for violence risk assessment that resembles the established guideline for suicide risk assessment and treatment. Combining elements from the mental status examination and an actuarial instrument is referred to as structured professional judgment. Miller described this as identifying historical risk factors that characterize the context of an individual’s aggressive behavior and risk factors After participating in this activity, the psychiatrist should be better able to:","PeriodicalId":90307,"journal":{"name":"Psychopharm review : timely reports in psychopharmacology and device-based therapies","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2010-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/01.IDT.0000388862.58629.3d","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"61612059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Vitamin D: Is It Ready for Psychiatric Prime Time? 维生素D:为精神病学准备好黄金时段了吗?

Psychopharm review : timely reports in psychopharmacology and device-based therapies Pub Date : 2010-09-01 DOI: 10.1097/01.IDT.0000387896.79557.35

J. Jefferson

引用次数: 0